Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
|Articles|April 29, 2010
P-MEC China
The pharma technology zone within CPhI China, P-MEC China focuses on equipment, machinery, packaging, analysis and technology, and is an integral part of Asia?s largest annual networking event for the pharmaceutical community. Held alongside CPhI China for pharmaceutical ingredients and APIs, ICSE for contract services and BioPh for biopharmaceutical solutions, P-MEC China is expected to attract over 20,000 visitors, including 7,000 from outside of China.
Advertisement
June 24, Shanghai New International Expo Centre
Providing an international platform for companies involved in an array of pharmaceutical production and analysis activities, P-MEC China is a highly targeted, pharma focused event, which brings together buyers and specifiers from more than 100 countries in conjunction with its collocated shows.
P-MEC has evolved in line with industry demand to include instrumental analysis, measuring and testing technology, materials testing, quality control, laboratory equipment as well as the traditional, large-scale capital equipment for which P-MEC is well known.
The domestic market in China for pharmaceuticals is already huge, yet it continues to grow, and there is an increasing need for high-value chemicals and contract services. There is also significant demand for innovative, high-quality equipment and machinery, particularly if it is ISO certified.
With all fields of the pharma industry gathered under one roof, and an extended conference programme, all the ingredients of success will be there. Join us at P-MEC China to discover the latest developments and innovations across every aspect of Pharma and Biotech Equipment, Laboratory and Analytical techniques while experiencing the unique face-to-face networking opportunities that only Asia’s largest pharmaceutical networking event can provide.
Take your share of the growth in China’s pharma market.
Register for free at
Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Advertisement
Advertisement